JP Morgan maintains Neutral on Agios, cuts target to $31
JP Morgan analyst Tessa Romero maintains a Neutral rating on Agios Pharmaceuticals (NASDAQ: AGIO) and lowers the price target to $31 from $36. The revised target reflects a more conservative outlook on the stock's potential.
*this image is generated using AI for illustrative purposes only.
JP Morgan analyst Tessa Romero has maintained a Neutral rating on Agios Pharmaceuticals (NASDAQ: AGIO) while lowering the price target to $31 from $36. The revised target indicates a change in the firm's valuation expectations for the stock.
Rating and Price Target Details
The brokerage's decision to retain the Neutral stance suggests that the risk-reward profile for Agios Pharmaceuticals remains balanced at current levels. The reduction in the price target to $31 signals a more conservative view on the stock's near-term upside potential.
| Metric | Value |
|---|---|
| Rating | Neutral |
| Previous Price Target | $36 |
| New Price Target | $31 |
The adjustment comes as market participants assess the company's operational progress and pipeline developments. Agios Pharmaceuticals continues to focus on its core therapeutic areas, though the specific drivers for the target cut were not detailed in the immediate release.
What specific operational or pipeline factors likely drove the more conservative valuation?
How might this price target adjustment influence investor sentiment toward Agios in the short term?
What upcoming catalysts could potentially shift the stock's risk-reward profile?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
